Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Neurizon Enters Strategic R&D Financing Facility with Dare Capital Loan Fund

Highlights:

- **Neurizon has executed a strategic R&D financing facility for up to $17.5 million with the Dare Capital Loan Fund, secured solely against the Company's R&D Tax Incentive refund**
- **An initial drawdown of approximately $8 million is expected to be available following execution, in relation to Neurizon's estimated FY2026 R&D Tax Incentive refund**
- **The facility is non-dilutive and aligned with the funding strategy announced by Neurizon on 23 December 2025, providing additional flexibility and reducing near-term reliance on other sources of funding**
- **Annual extension options provide for coverage of FY2027 and FY2028 R&D Tax Incentive claims, creating a flexible source of non-dilutive funding to support the Company's ongoing investment in the HEALEY ALS Platform Trial**

31 July 2026 – Melbourne Australia: Neurizon Therapeutics Limited (ASX: NUZ, OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has entered into a strategic R&D financing facility (the "Facility") for up to $17.5 million with the Dare Capital Loan Fund.

The Facility is a secured loan, with the lender holding first-ranking security solely over Neurizon's R&D Tax Incentive refund. An initial drawdown of approximately $8 million is expected to be available following execution. Interest accrues at 1.25% per month, capitalising monthly, with repayment triggered upon receipt of the R&D Tax Incentive refund from the Australian Taxation Office, with all outstanding amounts to be repaid by 31 December 2026 (subject to market standard extension terms). The Facility carries no establishment fee and includes annual extension options to support Neurizon's FY2027 and FY2028 R&D Tax Incentive claims.

The Facility directly strengthens the funding strategy announced by Neurizon on 23 December 2025 by providing non-dilutive access to capital earned through the Company's investment in eligible research and development expenditure. As a result of the Advance and Overseas Finding secured by Neurizon in September 2025, this include spend in the pivotal Phase 2/3 HEALEY ALS Platform Trial.

This Facility, which will support regular drawdowns against anticipated R&D Tax Incentive refunds, reduces the Company's reliance on other forms of funding, including the Obsidian convertible note facility, and broadens Neurizon's capital management flexibility as it advances toward the anticipated HEALEY topline readout in Q2 CY2027.

The Dare Capital Loan Fund, through which the Facility is provided, focuses specifically on lending to companies with proven R&D capabilities secured against Australian Government R&D Tax Incentive refunds.

Chief Financial Officer, Mr Dan O'Connell commented: "Entering into this facility is a meaningful step forward for Neurizon's capital management strategy. By financing our anticipated R&D Tax Incentive refund, we are bringing forward non-dilutive capital earned through our investment in the HEALEY trial — capital that both strengthens our funding position and reduces our near-term need to access other forms of funding, including drawing on the Obsidian convertible note facility. This is precisely the kind of additional flexibility our funding strategy was designed to accommodate.

We are also genuinely pleased with the quality and support of our counterparty. Dare and its supporting funds, bring real specialist expertise in R&D financing for life sciences companies. All parties have engaged with us in a thoroughly professional and collaborative manner, and we look forward to what we expect will be a long-term and strategically valuable relationship."

-ENDS-

This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited.

Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

For further information, please contact:

Marketing & Corporate Affairs
Lidija Damjanovic
Neurizon Therapeutics
lidija@neurizon.com
+61 (0) 425 700 504

Investor Relations
Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a late-clinical biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com